By Fineline Cube Alphamab Oncology (HKG: 9966) announced that the New Drug Application (NDA) for Anbenitamab (trade name: Ennituo, R&D code: KN026), co-developed with Shanghai JMT-Bio Technology Co., Ltd. (JMT-Bio), a subsidiary of CSPC Pharmaceutical Group Limited (1093.HK), in combination with docetaxel (albumin-bound) for injection (HB1801) as neoadjuvant treatment for human epidermal growth factor receptor 2-positive (HER2+) early or locally advanced breast cancer, has been accepted by China’s National Medical Products Administration (NMPA) and included in the priority review and approval procedure.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Application Type | New Drug Application (NDA) |
| Product | Anbenitamab (Ennituo) + HB1801 combination |
| Indication | Neoadjuvant treatment for HER2+ early or locally advanced breast cancer |
| Review Status | Priority review and approval procedure |
| Previous Approval | May 2026 for HER2+ gastric cancer/gastroesophageal junction cancer |
Drug Profile & Mechanism of Action
- Molecule: Anti-HER2 bispecific antibody
- Mechanism: Simultaneously binds two non-overlapping epitopes of HER2, resulting in comprehensive HER2 signal blockade
- Innovation: Novel bispecific approach offering enhanced target engagement compared to single-epitope antibodies
- Development Partnership: Co-developed with JMT-Bio (CSPC Pharmaceutical Group subsidiary)
Clinical Evidence – Phase III KN026-004/Neo-Healer Trial
| Endpoint | Anbenitamab + HB1801 | Standard Therapy (Trastuzumab + Pertuzumab + Docetaxel) | Statistical Significance |
|---|---|---|---|
| Total Pathological Complete Response (tpCR) | 62.4% (95% CI: 56.20–68.23) | Not disclosed (comparator arm) | One-sided P=0.0036 |
| Clinical Benefit | Superior efficacy with statistical and clinical value | Current standard of care | Established superiority |
| Safety Profile | Manageable overall safety profile | Comparable to established regimens | Favorable risk-benefit ratio |
The pivotal phase III study enrolled patients with HER2+ early or locally advanced breast cancer and demonstrated that Anbenitamab in combination with HB1801, with or without Carboplatin, significantly improved tpCR compared to the current standard therapy.
Market Context & Competitive Landscape
- HER2+ Breast Cancer Market: Represents approximately 15–20% of all breast cancer cases globally, with significant unmet need for more effective neoadjuvant therapies
- Current Standard: Dual HER2 blockade with trastuzumab and pertuzumab plus chemotherapy
- Competitive Advantage: Anbenitamab’s bispecific design may offer superior efficacy through enhanced HER2 pathway inhibition
- Commercial Potential: Building on recent approval in gastric cancer indication, expanding into the larger breast cancer market
Strategic Implications
- Pipeline Diversification: Second major indication following gastric cancer approval in May 2026
- Partnership Validation: Successful collaboration model with CSPC Pharmaceutical Group through JMT-Bio subsidiary
- Regulatory Strategy: Leveraging priority review pathway for accelerated market access
- Global Potential: Strong phase III data may support future international regulatory submissions
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, clinical trial results, and commercial potential. Actual outcomes may differ due to risks including final regulatory decisions, competitive dynamics, and market adoption.Fineline Info & Tech